Edwards Lifesciences said a U.S. federal court has granted the FTC an injunction blocking its proposed acquisition of JenaValve Technology, and as a result the deal will not proceed. Edwards disagreed with the ruling but stated it will continue advancing its own transcatheter aortic regurgitation programs, including the SOJOURN valve and JOURNEY pivotal trial.

Following the decision, the company raised its full-year 2026 adjusted EPS guidance to $2.90–$3.05 from $2.80–$2.95.

Source: Business Wire.